Why Cardiology? WIC Event – April 14

Med Students, Residents, & Fellows: Interested in the Field of Cardiology?

We want to show you how rewarding it is to be a cardiologist! All trainees interested in Cardiology (Fellows, Residents, Medical Students, Pre-Med Students) are invited to join the Minnesota Chapter of the American College of Cardiology (ACC-MN) and its Women in Cardiology (WIC) section to explore this important and exciting field of medicine.

Join us for networking, a panel discussion and career exploration with Minnesota-based cardiologists representing the ACC-MN WIC Section. Refreshments will be provided.

Physician Day at the MN Capitol with the Minnesota Medical Association – Feb. 8

Physicians and physicians-in-training from across the state will gather again in-person at the state Capitol on February 8, to advocate on behalf of medicine.

The annual get-together, which has been held virtually the last two years, is now referred to as Physicians’ Day at the Capitol. It will include a review of top priorities and tips on how to interact effectively with elected officials.

The MMA is partnering with several specialty societies and Zumbro Valley Medical Society to promote the event including the Minnesota Academy of Family Physicians; the Minnesota Academy of Ophthalmology; the Minnesota Chapter, American College of Cardiology; the Minnesota Chapter, American College of Emergency Physicians; the Minnesota Chapter, American College of Physicians; the Minnesota Osteopathic Medical Society; and the Minnesota Psychiatric Society.

“The more white coats we get to the Capitol and in meetings with legislators, the louder our voice,” said MMA President Will Nicholson, MD. “Now more than ever, physicians need to be meeting with representatives and senators to continue advocating for the practice of medicine and their patients.”

To register and for more information, visit here: https://mnmed.org/education-and-events/Day-at-the-Capitol

New ACC/AHA Aortic Disease Guideline

The newest clinical guideline from the ACC and the American Heart Association (AHA) aims to guide clinicians in the diagnosis and management of patients with aortic disease. Specifically, the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease provides recommendations regarding diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance across multiple clinical presentation subsets, ranging from asymptomatic patients to those with acute aortic syndromes.

Among the highlights, the guideline encourages the use of centers with Multidisciplinary Aortic Teams in determining the appropriate timing of intervention. There is also added emphasis on the role of shared decision-making, especially in the management of patients with aortic disease both before and during pregnancy due to the “cardiovascular risks of pregnancy, the diameter thresholds for prophylactic aortic surgery, and the mode of delivery.” Read more.

To access clinician and patient tools related to the Guideline, including CardioSmart resources and a JACC Aortic Disease Interactive Guideline Tool tied to family screening, visit ACC’s Aortic Disease Guideline Hub.

2022 FIT Symposium: Networking and the Job Search on Nov. 10

Save the Date! Cardiology Fellows-in-Training will have the opportunity to hear from some of Minnesota’s top cardiologists about their real-world experiences during the transition from training to practice. We will have a panel discussion for approximately 90 minutes, with time outside of that for questions and networking.


  • Catherine (Katie) Benziger, MD, MPH, FACC, FAHA – Essentia Health
  • Michelle Carlson, MD, FACC – Hennepin Healthcare
  • Selma Carlson, MD, FACC – Minneapolis VA & University of Minnesota Medical School
  • Michael Cullen, MD, FACC – Mayo Clinic
  • Andrea Elliott, MD, FACC – University of Minnesota
  • William (Bill) Katsiyiannis, MD, FACC – Minneapolis Heart Institute
  • Sheetal (Sunny) Kaul, MD, MBBS, FACC – HealthPartners
  • Carmelo Panetta, MD, FACC – University of MN Physicians
  • Retu Saxena, MD, FACC – Minneapolis Heart Institute
  • Gautam R. Shroff, MBBS, FACC – Hennepin Healthcare
  • Mengistu A. Simegn, MD, FACC, FASE – Hennepin Healthcare
  • Stephen J. Smalley, MD, FACC – Essentia Health
  • Randall (Randy) Stark, MD, FACC – Metropolitan Heart & Vascular Institute
  • Sharath S. Subramanian, MBBS, MD, FACC – Centracare Heart & Vascular Center

CME Webinar: Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Program Overview:

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration, but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs will provide cardiologists with information about the etiology of anemia in CKD, the effects on CV disease, HRQOL, and function, advantages and limitations of current management strategies, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

  • Discuss the etiology of anemia in chronic kidney disease
  • Summarize how anemia affects functioning, quality of life, and health outcomes, for patients with cardiovascular disease and chronic kidney disease
  • Assess the benefits and limitations of available modalities for treating anemia in chronic kidney disease
  • Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease

Steering Committee:

Erin Michos, MD, MHS
Associate Professor of Medicine
Division of Cardiology
Johns Hopkins School of Medicine

Matthew Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine

Jointly provided by USFH and Rockpointe.

This educational activity is supported by an educational grant from GlaxoSmithKline.

1 2 3